Skip to main content
. 2023 Oct 4;6(12):e202302116. doi: 10.26508/lsa.202302116

Figure S1. Effects of nicotinamide mononucleotide (NMN) on improving lysosomal function.

Figure S1.

(A) Cross-section of the heart with hematoxylin and eosin staining. (B) Amino acid metabolism analysis of NMN-treated mice. LC-MS/MS metabolomic analysis of amino acids in 9-mo-old WT and p32cKO mice with treatment of NMN from 2 to 9 mo of age was performed. Amino acids are significantly different between WT and p32cKO mice. Error bars show the mean ± SEM. Data were analyzed by one-way analysis of variance with Tukey’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001. (C) Electron micrographs showing lysosomes in cardiac myofibrils of mice treated with NMN from 2 to 9 mo of age or of those that were untreated. The lysosome size and density differed between WT and p32cKO mice. Heart tissue with or without NMN supplementation did not show changes in lysosome size. Scale bars, 1 μm. Quantification of the average lysosomal area is shown as the mean ± SEM (n = 3) (plot in the right panel). Data were analyzed by one-way analysis of variance with Tukey’s multiple comparisons test. *P < 0.05. (D) Immunostaining of Lamp2 (red) and DAPI (blue) in heart tissue of WT and p32cKO mice and of p32cKO mice treated with NMN from 2 to 9 mo. Lamp2 stained in the near-nuclear region is indicated by the white arrows. Scale bar, 20 μm.